ProMIS Neurosciences (PMN) Current Assets (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Current Assets came in at $65.6 million in Q1 2026, up 380.8% YoY from $13.6 million in Q1 2025, and up 614.55% on a QoQ basis from $9.2 million in Q4 2025.
ProMIS Neurosciences (PMN) Current Assets (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Current Assets data on file, last reported at $65.6 million in Q1 2026.
- Quarterly Current Assets rose 380.8% year-over-year to $65.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.6 million (up 380.8% YoY) and the FY2025 annual result came in at $9.2 million, down 51.45% from the prior year.
- Current Assets rose to $65.6 million in Q1 2026, from $9.2 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $65.6 million in Q1 2026 to a low of $1.4 million in Q2 2024.
- A 5-year average of $14.2 million and a median of $9.8 million in 2022 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets plunged 85.44% — and 2025, when it jumped 574.63%.
- Tracing PMN's Current Assets over 5 years: stood at $6.9 million in 2022, then jumped by 97.28% to $13.6 million in 2023, then jumped by 38.86% to $18.9 million in 2024, then plunged by 51.45% to $9.2 million in 2025, then soared by 614.55% to $65.6 million in 2026.
- The last three Current Assets figures came in at $65.6 million (Q1 2026), $9.2 million (Q4 2025), and $21.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 1.76 Bn |
| 10 | ProMIS Neurosciences | 135.44 Mn | 81.98 Mn | - | 56.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.69 Mn |
| Mar 31, 2026 | 65.61 Mn |
| Dec 31, 2025 | 9.18 Mn |
| Sep 30, 2025 | 21.46 Mn |
| Jun 30, 2025 | 9.51 Mn |
| Mar 31, 2025 | 13.65 Mn |
| Dec 31, 2024 | 18.91 Mn |
| Sep 30, 2024 | 24.51 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Mar 31, 2024 | 3.55 Mn |
| Dec 31, 2023 | 13.62 Mn |
| Sep 30, 2023 | 17.86 Mn |
| Jun 30, 2023 | 1.48 Mn |
| Mar 31, 2023 | 4.41 Mn |
| Dec 31, 2022 | 6.90 Mn |
| Sep 30, 2022 | 5.36 Mn |
| Jun 30, 2022 | 10.16 Mn |
| Dec 31, 2021 | 17.71 Mn |